[4,6-diamino-2-[4-[(2-fluorophenyl)methyl]-2H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]-methylcarbamic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: [4,6-diamino-2-[4-[(2-fluorophenyl)methyl]-2H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl]-methylcarbamic acid
• 化学式: C₁₉H₁₇FN₈O₂
• 分子量: 408.4
• InChiKey: VKHFSUZTMXAJCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  160
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• [EN] PROCESS FOR THE PREPARATION OF METHYL 4,6-DIAMINO-2-[L-(2-FHIOROBENZVR)-LH-PYRAZOLO I3,4-BLPVRIDIN-3-VN-5-PYRIMIDINYL(METHVL)CARBAMATE AND ITS POLYMORPHS THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION DE MÉTHYL 4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-3-YL]-5-PYRIMIDINYLE(MÉTHYL)CARBAMATE ET DE SES POLYMORPHES
  申请人：MSN LABORATORIES PRIVATE LTD

  公开号：WO2017025981A1

  公开（公告）日：2017-02-16

  The present invention relates to process for the preparation of methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-lH-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl(methyl)carbamate and its polymorphs thereof compound of formula-1, represented by the following structure.

  本发明涉及一种用于制备甲基4,6-二氨基-2-[1-(2-氟苯甲基)-1H-吡唑并[3,4-b]吡啶-3-基]-5-嘧啶基(甲基)氨基甲酸酯及其多晶形式的化合物的制备方法，该化合物的分子式如下所示。
• COMPOSITIONS AND METHODS THAT PROMOTE HYPOXIA OR THE HYPOXIA RESPONSE FOR TREATMENT AND PREVENTION OF MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS DISORDERS
  申请人：The General Hospital Corporation

  公开号：EP3334484A2

  公开（公告）日：2018-06-20
• [EN] COMPOSITIONS AND METHODS THAT PROMOTE HYPOXIA OR THE HYPOXIA RESPONSE FOR TREATMENT AND PREVENTION OF MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS DISORDERS<br/>[FR] COMPOSITIONS ET MÉTHODES QUI FAVORISENT L'HYPOXIE OU LA RÉPONSE HYPOXIQUE POUR LE TRAITEMENT ET LA PRÉVENTION D'UN DYSFONCTIONNEMENT MITOCHONDRIAL ET DE TROUBLES DU STRESS OXYDATIF
  申请人：MASSACHUSETTS GEN HOSPITAL

  公开号：WO2017027810A2

  公开（公告）日：2017-02-16

  Methods of promoting hypoxia or the hypoxia response for the treatment or prevention of mitochondrial dysfunction and oxidative stress disorders are described. Methods for screening for targets of mitochondrial dysfunction and oxidative stress disorders are also described.